Gastroenterology Doctors in Walnut Creek, CA Accepting Medicare

26 Gastroenterology doctors found. Showing 21 - 26

Kanwar R. S. Gill, M.D. Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1450 Treat Blvd, Ste 200, Walnut Creek, CA 94597 Phone: 925-296-7340    Fax: 925-296-9042

Steven M. Fredman, MD Internal Medicine - Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 1425 S Main St, Walnut Creek, CA 94596 Phone: 925-295-4000

Rohit Anand, MD Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1479 Ygnacio Valley Rd Ste 200, Walnut Creek, CA 94598 Phone: 925-296-7340

Dr. Sam Saeed Zamani, M.D. Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 112 La Casa Via, Suite 320, Walnut Creek, CA 94598 Phone: 925-939-5599    Fax: 925-939-4099

Suyi Chang, MD Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1425 S Main St, Walnut Creek, CA 94596 Phone: 925-295-4000

Dr. David H.y. Lin, M.D. Internal Medicine - Gastroenterology Medicare: Medicare Enrolled Practice Location: 112 La Casa Via Ste 320, Walnut Creek, CA 94598 Phone: 925-831-9200    Fax: 925-831-9317

News Archive

Formedix's design tools integrated with Nextrials' EDC and clinical trial data management platform

Nextrials, Inc., a leader in clinical research software and services, today announced that its electronic data capture (EDC) and clinical trial data management platform, Prism™, is now integrated with the study design tools offered by Formedix. Formedix's industry leading Origin™ products include database design tools based on the data standards developed by the Clinical Data Interchange Standards Consortium (CDISC), a platform that Nextrials fully supports.

Antibe Therapeutics increases non-brokered private placement to a total of 2.27 million units

Antibe Therapeutics Inc. ("Antibe" or the "Corporation") (TSXV:ATE) announces an increase to the size of its non-brokered private placement to a total of approximately 2.27 million units (the "Units") at a price of $0.55 per Unit, from the previously announced total of approximately 1.8 million Units, each Unit comprised of one Common Share of the Corporation and one-half of one Common Share purchase warrant ("Warrant") with each whole Warrant entitling the holder to purchase an additional Common Share ("Warrant Share") at a price of $0.80 per Warrant Share for a term of thirty-six (36) months following the date of issuance, for gross proceeds of up to $1.25 million (the "Offering").

WHO's classification of game addiction as mental health disorder may help people to seek treatment

The World Health Organization's classification of video game addiction as a mental health disorder is a significant step toward getting people the help they need, said Douglas Gentile, an Iowa State University professor of psychology and expert on video games and addiction.

FDA issues safety labeling changes for female sexual dysfunction treatment

The U.S. Food and Drug Administration today issued a safety labeling change order to Sprout Pharmaceuticals for their drug, Addyi (flibanserin), that requires the company to revise important safety information that women and their health care professionals need to have when considering use of the drug.

Skin may help to predict future heart problems

Our skin tells us when we've spent too much time in the sun or when the dry air of winter has sucked away too much moisture. Now Jefferson researchers find that the skin can also foretell issues unrelated to the protective barrier.

Read more Medical News

› Verified 4 days ago

• 1
• 2(current)